info@mail.ucallm.com
From Inflammatory Microenvironments to Fibrotic Remodeling — Empowering Precision Investigation of Immune–ECM Crosstalk with Validated Antibody Solutions
Fibrosis represents a dynamic and multifaceted tissue remodeling process driven by continuous interactions among immune cells, stromal populations, extracellular matrix (ECM), and mechanosensitive signaling networks. Emerging evidence demonstrates that fibrosis is not simply a fibroblast-centric disorder, but a coordinated pathological response involving immune activation, inflammatory signaling, fibroblast reprogramming, ECM accumulation, and altered tissue mechanics.
The immune–stromal ecosystem orchestrates key events throughout fibrosis development, including:
- Macrophage polarization and immune niche formation
- Inflammatory cytokine and chemokine network activation
- Fibroblast-to-myofibroblast transition
- TGF-β-mediated profibrotic signaling
- ECM deposition, remodeling, and matrix stiffening
- Mechanotransduction-driven tissue adaptation and disease progression
We provide comprehensive antibody solutions for dissecting the molecular mechanisms underlying fibrosis — enabling researchers to investigate immune cell activation, stromal cell transformation, ECM remodeling, and fibrosis-associated signaling pathways across diverse disease models.
Our validated antibody portfolio supports researchers in:
Characterizing fibrosis-associated immune landscapes and cellular phenotypes
2. Decoding macrophage–fibroblast communication and inflammatory crosstalk
3. Monitoring fibroblast activation, myofibroblast differentiation, and ECM deposition
4. Profiling TGF-β, mechanotransduction, and downstream profibrotic signaling pathways
5. Mapping fibrosis-associated cellular niches and tissue microenvironments
6. Enabling multiplex immunofluorescence and spatial analysis of immune–stromal interactions
Immune–Stromal Interaction Biomarker Antibody Portfolio
—Comprehensive Solutions for Immune Activation, Fibroblast Remodeling, ECM Dynamics, and Fibrotic Disease Mechanisms
Fibrotic progression involves interconnected biological modules linking inflammation, stromal activation, extracellular matrix remodeling, and tissue mechanical adaptation.
Our antibody portfolio targets key pathways involved in:
Research Module | Representative Biomarkers | Research Applications |
Macrophage Activation & Immune Phenotyping | CD68, CD163, MRC1 (CD206), CD80, CD86, HLA-DR, ARG1, IL10 | Characterization of macrophage polarization, inflammatory states, and immune regulation within fibrotic tissues |
Immune–Fibrotic Cytokine Signaling | TGFB1, TGFBR1, TGFBR2, SMAD2, SMAD3, p-SMAD2 (Ser465/467), p-SMAD3 (Ser423/425), IL6, TNF | Investigation of cytokine-driven fibroblast activation and profibrotic signaling cascades |
Fibroblast Activation & Myofibroblast Transition | ACTA2 (α-SMA), S100A4 (FSP1), VIM, CTGF (CCN2), FN1, POSTN, PDGFRB | Monitoring fibroblast differentiation, myofibroblast formation, and fibrotic remodeling |
Mechanotransduction & Fibrotic Signaling | YAP1, WWTR1 (TAZ), MRTFA (MKL1), MRTFB (MKL2), SRF, ITGB1, ITGA5, PTK2 (FAK), p-PTK2 Tyr397 | Analysis of matrix stiffness sensing and mechanical regulation of fibrosis |
ECM Deposition & Remodeling | COL1A1, COL1A2, COL3A1, COL4A1, COL5A2, COL6A1, COL6A3, FN1 | Evaluation of collagen accumulation and extracellular matrix organization |
Matrix Degradation & Remodeling Enzymes | MMP2, MMP9, MMP13, MMP14 (MT1-MMP), TIMP1, TIMP2, LOX, LOXL2, TNC | Investigation of ECM turnover, matrix maturation, and tissue remodeling |
Fibrosis Immune–Stromal Regulatory Network
—Key Targets Driving Macrophage Activation, Fibroblast Transformation, and ECM Remodeling
Fibrosis progression is governed by a complex regulatory network connecting immune activation with stromal remodeling. Central regulators including TGF-β signaling, macrophage polarization programs, YAP/TAZ mechanotransduction, and ECM remodeling pathways coordinate fibroblast activation and persistent tissue fibrosis.
Key Target | Biological Role | Antibody Research Application |
TGF-β1 | Master profibrotic cytokine linking immune activation to fibroblast differentiation and ECM production | Detection of fibrosis initiation and cytokine-mediated remodeling responses |
SMAD2/3 & p-SMAD2/3 | Canonical downstream mediators of TGF-β signaling | Monitoring activation of profibrotic transcriptional programs |
CD163 | Marker associated with alternatively activated macrophage populations | Characterization of fibrosis-associated macrophage niches |
Arginase-1 | Regulator of macrophage metabolic polarization and tissue repair responses | Analysis of macrophage phenotype switching during fibrosis |
α-SMA (ACTA2) | Hallmark marker of activated myofibroblasts | Identification of fibroblast activation and contractile phenotype acquisition |
CTGF (CCN2) | Fibrosis-associated growth factor downstream of TGF-β signaling | Evaluation of persistent profibrotic activation |
YAP/TAZ | Mechanosensitive transcriptional regulators responding to ECM stiffness | Investigation of matrix-driven fibrosis amplification |
FAK/PTK2 | Integrin-associated kinase regulating adhesion and mechanical signaling | Study of ECM sensing and stromal activation |
COL1A1 | Major fibrillar collagen component | Quantification of ECM deposition and fibrosis severity |
FN1 | ECM scaffold protein involved in fibroblast activation | Analysis of matrix remodeling and tissue repair responses |
Featured Immune–Stromal Fibrosis Research Panels
—Integrated Antibody Panels for Profiling Fibrotic Microenvironments and Disease Progression
Immune–stromal interactions represent a central mechanism controlling fibrosis initiation, progression, and therapeutic response. Integrated biomarker profiling enables researchers to investigate cellular communication networks and define fibrosis-associated molecular signatures.
Fibrotic Immune Microenvironment Panel—Decoding macrophage activation and inflammatory niches
Key Markers
CD163 | CD68 | MRC1 | CD80 | CD86 | HLA-DR | ARG1 | IL10 |
Fibroblast Activation & Myofibroblast Transition Panel—Monitoring stromal cell activation and fibrotic transformation
Key Markers
α-SMA | FSP1 / S100A4 | Vimentin | CTGF | Fibronectin | COL1A1 | POSTN |
TGF-β Fibrosis Signaling Panel—Investigating canonical profibrotic signaling pathways
Key Markers
TGF-β1 | TGFBR1 | TGFBR2 | SMAD2/3 | p-SMAD2/3 | ERK1/2 | p-ERK1/2 |
ECM Remodeling & Matrix Stiffness Panel—Characterizing extracellular matrix deposition and remodeling
Key Markers
COL1A1 | COL3A1 | COL4A1 | FN1 | LOXL2 |
COL6A3, | MMP2 | MMP9 | LOX | TNC |
Mechanotransduction & Fibrotic Progression Panel—Understanding mechanical regulation of fibrosis
Key Markers
YAP | TAZ | MRTF | SRF | Integrin | FAK |
Why Researchers Choose Our Immune–Stromal Fibrosis Antibody Solutions
Validated Immune Markers. Comprehensive Fibrosis Panels. Mechanistic Insights into Tissue Remodeling
Our antibody portfolio supports complete fibrosis research workflows
Research Challenge | Our Solution |
How can I characterize fibrosis-associated immune populations? | CD163, CD80, CD86, MHC II, Arginase-1 macrophage profiling solutions |
How can I study immune-driven fibroblast activation? | TGF-β1, TGFBR1/2, SMAD2/3 pathway antibodies |
How can I identify activated myofibroblasts? | α-SMA, CTGF, FSP1, Vimentin, Fibronectin marker panels |
How can I analyze ECM remodeling? | COL1A1, COL3A1, FN1, MMP, LOX family solutions |
How can I investigate mechanical regulation of fibrosis? | YAP/TAZ, MRTF, SRF, Integrin–FAK signaling antibodies |
How can I visualize immune–stromal spatial organization? | Multiplex IF/IHC-compatible validated antibody solutions |
Key reference
Xu Y, Ying L, Lang JK, Hinz B, Zhao R. Modeling mechanical activation of macrophages during pulmonary fibrogenesis for targeted anti-fibrosis therapy. Sci Adv. 2024 Mar 29;10(13):eadj9559.
Bhattacharya M, Ramachandran P. Immunology of human fibrosis. Nat Immunol. 2023 Sep;24(9):1423-1433.
Ruta A, Krishnan K, Woo J, Mejías JC, Gray-Gaillard EF, Maestas DR Jr, Nguyen HH, Rindone AN, Cherry C, Patatanian M, Yu FH, Yang B, Amelung C, King CD, Schilling B, Gerecht S, Fertig EJ, Davenport Huyer L, Pardoll DM, Elisseeff JH. γδ T cell-stromal networks modulate matrix composition and vascularity in foreign body response. Nat Commun. 2026 Apr 17;17(1):5334.
Ning D, Tavakol DN, Graney PL, Lee E, Hung CT, Vunjak-Novakovic G. Immune-stromal interactions at the crossroads of tissue injury, repair, and tumor progression. Med. 2026 Jul 21:101222.
Perez-Shibayama C, Cadosch N, Schmidt D, Flammer AJ, Ruschitzka F, Gil-Cruz C, Ludewig B. Myocardial Immune Niches in Homeostasis and Inflammation. Immunol Rev. 2026 Jul;340(1):e70139.